SG10201705669QA - Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof - Google Patents
Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereofInfo
- Publication number
- SG10201705669QA SG10201705669QA SG10201705669QA SG10201705669QA SG10201705669QA SG 10201705669Q A SG10201705669Q A SG 10201705669QA SG 10201705669Q A SG10201705669Q A SG 10201705669QA SG 10201705669Q A SG10201705669Q A SG 10201705669QA SG 10201705669Q A SG10201705669Q A SG 10201705669QA
- Authority
- SG
- Singapore
- Prior art keywords
- oxazepin
- methylpropanamide
- dihydrobenzo
- polymorphs
- imidazo
- Prior art date
Links
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916657P | 2013-12-16 | 2013-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201705669QA true SG10201705669QA (en) | 2017-08-30 |
Family
ID=52023532
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705673QA SG10201705673QA (en) | 2013-12-16 | 2014-12-15 | Polymorphs Of 2-(4-(2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4] Oxazepin-9-Yl)-1H-Pyrazol-1-Yl)-2-Methylpropanamide, Methods Of Production, And Pharmaceutical Uses Thereof |
| SG10201705669QA SG10201705669QA (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
| SG11201604903VA SG11201604903VA (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705673QA SG10201705673QA (en) | 2013-12-16 | 2014-12-15 | Polymorphs Of 2-(4-(2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4] Oxazepin-9-Yl)-1H-Pyrazol-1-Yl)-2-Methylpropanamide, Methods Of Production, And Pharmaceutical Uses Thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604903VA SG11201604903VA (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9266903B2 (en) |
| EP (1) | EP3083640A1 (en) |
| JP (2) | JP6302089B2 (en) |
| KR (2) | KR20180093138A (en) |
| CN (2) | CN105829323B (en) |
| AR (1) | AR098762A1 (en) |
| AU (3) | AU2014365079B2 (en) |
| BR (1) | BR112016009665A8 (en) |
| CA (1) | CA2927125A1 (en) |
| HK (1) | HK1223101A1 (en) |
| IL (2) | IL244915A0 (en) |
| MX (1) | MX356804B (en) |
| RU (2) | RU2018119749A (en) |
| SG (3) | SG10201705673QA (en) |
| TW (2) | TW201731852A (en) |
| WO (1) | WO2015091305A1 (en) |
| ZA (1) | ZA201602534B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2981159A1 (en) * | 2015-06-29 | 2017-01-05 | F. Hoffmann-La Roche Ag | Methods of treatment with taselisib |
| EP4272735A1 (en) * | 2015-06-30 | 2023-11-08 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| MX2019012507A (en) | 2017-04-28 | 2019-12-19 | Hoffmann La Roche | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2 -oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxaze pin-9-yl)amino)propanamide, and methods of production. |
| KR20200091395A (en) * | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | Crystal form of diazabicyclooctane derivative and method for preparing same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5540101B2 (en) | 2009-09-28 | 2014-07-02 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Benzoxazepine PI3K inhibitor compounds and methods of use |
| CN104379163A (en) * | 2012-06-08 | 2015-02-25 | 霍夫曼-拉罗奇有限公司 | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| NZ711192A (en) * | 2013-03-13 | 2019-04-26 | Hoffmann La Roche | Process for making benzoxazepin compounds |
-
2014
- 2014-12-15 WO PCT/EP2014/077666 patent/WO2015091305A1/en active Application Filing
- 2014-12-15 RU RU2018119749A patent/RU2018119749A/en unknown
- 2014-12-15 JP JP2016558275A patent/JP6302089B2/en active Active
- 2014-12-15 TW TW105143616A patent/TW201731852A/en unknown
- 2014-12-15 RU RU2016127039A patent/RU2658009C2/en not_active IP Right Cessation
- 2014-12-15 AU AU2014365079A patent/AU2014365079B2/en not_active Ceased
- 2014-12-15 SG SG10201705673QA patent/SG10201705673QA/en unknown
- 2014-12-15 US US14/570,019 patent/US9266903B2/en active Active
- 2014-12-15 CN CN201480068672.4A patent/CN105829323B/en active Active
- 2014-12-15 EP EP14811921.7A patent/EP3083640A1/en not_active Withdrawn
- 2014-12-15 KR KR1020187023324A patent/KR20180093138A/en not_active Application Discontinuation
- 2014-12-15 KR KR1020167015862A patent/KR101902664B1/en active IP Right Grant
- 2014-12-15 MX MX2016007581A patent/MX356804B/en active IP Right Grant
- 2014-12-15 CA CA2927125A patent/CA2927125A1/en not_active Abandoned
- 2014-12-15 SG SG10201705669QA patent/SG10201705669QA/en unknown
- 2014-12-15 BR BR112016009665A patent/BR112016009665A8/en not_active Application Discontinuation
- 2014-12-15 SG SG11201604903VA patent/SG11201604903VA/en unknown
- 2014-12-15 CN CN201811256901.1A patent/CN109293674A/en active Pending
- 2014-12-15 AR ARP140104667A patent/AR098762A1/en unknown
- 2014-12-15 TW TW103143724A patent/TWI638818B/en not_active IP Right Cessation
-
2016
- 2016-01-08 US US14/991,658 patent/US9481690B2/en active Active
- 2016-04-05 IL IL244915A patent/IL244915A0/en unknown
- 2016-04-14 ZA ZA201602534A patent/ZA201602534B/en unknown
- 2016-09-29 HK HK16111381.6A patent/HK1223101A1/en unknown
- 2016-11-14 IL IL248965A patent/IL248965A0/en unknown
-
2017
- 2017-06-06 AU AU2017203817A patent/AU2017203817B2/en not_active Ceased
- 2017-06-06 AU AU2017203819A patent/AU2017203819B2/en not_active Ceased
- 2017-12-20 JP JP2017244553A patent/JP2018080179A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2603900A4 (en) | System and methods for the production of personalized drug products | |
| SG11201405221PA (en) | Catheter die and method of fabricating the same | |
| EP3041569A4 (en) | Detection of reduced-control cardiac zones | |
| HUE052904T2 (en) | Imidazoline derivatives, preparation methods thereof, and their applications in medicine | |
| EP3173412A4 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| PL2834248T3 (en) | Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | |
| IL267464A (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
| EP2834224A4 (en) | Process for the preparation of benzimidazole derivatives and salts thereof | |
| IL248965A0 (en) | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof | |
| SG11201405270UA (en) | Method for the production of polyols and uses thereof | |
| IL281087A (en) | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide | |
| HK1201060A1 (en) | Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal 2-(23-)-1- | |
| EP3004085A4 (en) | Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | |
| EP3068391A4 (en) | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | |
| EP2842940A4 (en) | Sulforaphane-derived compounds, production method thereof and the medical, food and cosmetic use of same | |
| HK1212968A1 (en) | Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs | |
| ZA201407558B (en) | Itq-49 material, method for the production thereof and use of same | |
| EP2835372A4 (en) | Thiophene [2, 3-d]pyrimidine derivative, and preparation method and use thereof | |
| HK1209753A1 (en) | Process for the preparation of heterocyclic ester derivatives | |
| HK1208454A1 (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| ZA201504676B (en) | An improved process for the preparation of moxifloxacin hydrochloride | |
| IL236480B (en) | Process for the preparation of 2-substituted 5-(1-alkylthio)alkyl-pyridine n-oxides | |
| AP3759A (en) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same | |
| EP2964659A4 (en) | Process for the preparation of deferasirox | |
| ZA201201061B (en) | Process for the preparation of bromopyrimidine derivative |